| Original language | English |
|---|---|
| Article number | 736626 |
| Journal | Frontiers in Genetics |
| Volume | 12 |
| DOIs | |
| Publication status | Published - 2021 Aug 5 |
Keywords
- CYP
- N-acetyltransferase (NAT)
- pharmacogenomics (PGx)
- population genetics
- precision medicine
ASJC Scopus subject areas
- Molecular Medicine
- Genetics
- Genetics(clinical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Editorial : Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation. / Hiratsuka, Masahiro; Zhou, Yitian; Lauschke, Volker M.
In: Frontiers in Genetics, Vol. 12, 736626, 05.08.2021.Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Editorial
T2 - Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation
AU - Hiratsuka, Masahiro
AU - Zhou, Yitian
AU - Lauschke, Volker M.
N1 - Funding Information: MH was supported by grants from the Japan Agency for Medical Research and Development (AMED) (Grant number JP19kk0305009). VL receives support from the Swedish Research Council (grant agreement numbers: 2016-01153, 2016-01154, and 2019-01837), by the EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant number 875510), by the Swedish Strategic Research Programmes in Diabetes (SFO Diabetes) and Stem Cells and Regenerative Medicine (SFO StratRegen), as well as by the European Union’Horizon 2020 research and innovation program U-PGx (grant agreement number 668353). Furthermore, VL acknowledges support from Merck KGaA, Eli Lilly and Company, and by the Robert Bosch Foundation. Funding Information: Funding. MH was supported by grants from the Japan Agency for Medical Research and Development (AMED) (Grant number JP19kk0305009). VL receives support from the Swedish Research Council (grant agreement numbers: 2016-01153, 2016-01154, and 2019-01837), by the EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant number 875510), by the Swedish Strategic Research Programmes in Diabetes (SFO Diabetes) and Stem Cells and Regenerative Medicine (SFO StratRegen), as well as by the European Union'Horizon 2020 research and innovation program U-PGx (grant agreement number 668353). Furthermore, VL acknowledges support from Merck KGaA, Eli Lilly and Company, and by the Robert Bosch Foundation.
PY - 2021/8/5
Y1 - 2021/8/5
KW - CYP
KW - N-acetyltransferase (NAT)
KW - pharmacogenomics (PGx)
KW - population genetics
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85113169923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113169923&partnerID=8YFLogxK
U2 - 10.3389/fgene.2021.736626
DO - 10.3389/fgene.2021.736626
M3 - Editorial
AN - SCOPUS:85113169923
VL - 12
JO - Frontiers in Genetics
JF - Frontiers in Genetics
SN - 1664-8021
M1 - 736626
ER -